ProCE Banner Activity

Safety of JAK Inhibitors in RA

Clinical Thought
What is the safety of JAK inhibitors in the treatment of RA? Read expert answers to audience questions from a CCO Webinar on current best practices and emerging options for patients with RA.

Released: December 18, 2020

Expiration: December 17, 2021

Share

Faculty

Sheetal Desai

Sheetal Desai, MD, MSEd

Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California

Eric M. Ruderman

Eric M. Ruderman, MD

Professor
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Faculty Disclosure

Primary Author

Sheetal Desai, MD, MSEd

Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California

Sheetal Desai, MD, MSEd, has disclosed that she has received consulting fees and fees for non-CME/CE services from Janssen.

Eric M. Ruderman, MD

Professor
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois

Eric M. Ruderman, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Gilead Sciences, Janssen, Lilly, Novartis, Pfizer, and Selecta.